Rein Therapeutics Inc.
RNTX
$1.27
$0.1412.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -51.32% | -31.72% | -53.56% | 20.15% | 179.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.98% | -22.15% | -20.61% | 207.08% | 334.57% |
| Operating Income | 23.98% | 22.15% | 20.61% | -207.08% | -334.57% |
| Income Before Tax | 23.71% | 22.66% | -479.44% | -220.03% | -400.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.71% | 22.66% | -458.40% | -220.03% | -400.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.71% | 22.66% | -458.40% | -220.03% | -400.39% |
| EBIT | 23.98% | 22.15% | 20.61% | -207.08% | -334.57% |
| EBITDA | 23.96% | 21.73% | 20.04% | -208.96% | -336.90% |
| EPS Basic | 37.21% | 70.70% | -22.77% | 32.91% | -14.13% |
| Normalized Basic EPS | 37.19% | 70.70% | 83.50% | 32.68% | -8.76% |
| EPS Diluted | 37.21% | 70.70% | -22.77% | 32.91% | -14.13% |
| Normalized Diluted EPS | 37.19% | 70.70% | 83.50% | 32.68% | -8.76% |
| Average Basic Shares Outstanding | 21.48% | 163.99% | 354.83% | 377.03% | 338.46% |
| Average Diluted Shares Outstanding | 21.48% | 163.99% | 354.83% | 377.03% | 338.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |